DAY 2 | #GUARDSymposium2026 A key question in localized #BladderCancer: Are we ready to move ctDNA from an exciting biomarker to a tool that actually changes treatment decisions? The session, moderated by @Uro_Oncologist and Dr. Óscar Rodríguez Faba, opened with Dra. Sara Coca reviewing how biomarkers may help refine therapeutic strategy in localized disease. 🧬 ctDNA is particularly compelling because it may help us: 🔹 identify molecular residual disease 🔹 refine recurrence risk beyond clinicopathologic features 🔹 select patients who may benefit from treatment escalation 🔹 potentially spare treatment in those with very low residual risk 🔹 monitor disease dynamically over time But the crucial issue is not whether ctDNA is prognostic. It is whether acting on ctDNA improves outcomes. 🎯 My takeaway: the future of bladder cancer will not be biomarker-rich just for the sake of more information. The real value will come when biomarkers allow us to treat more precisely, more selectively, and at the right moment. The question is getting closer to practice: When should ctDNA become actionable? @Uro_Oncologist @DrFelixGuerrero @dralvaropinto @drenriquegrande @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1 @GuardConsortium #ctDNA #Biomarkers #PrecisionOncology #GUOncology #MolecularResidualDisease

Great discussion on localized bladder cancer at #GUARD2026. A pleasure to co-chair with Alfonso Gómez de Liaño and outstanding speakers. From HR-NMIBC to perioperative therapy in MIBC and ctDNA, one message stood out: better care requires a truly multidisciplinary approach.

🟠 DIRECTO #GUARDSymposium2026 Comienza la mesa dedicada al cáncer de vejiga localizado, moderada por el Dr. Alfonso Gómez de Liaño @Uro_Oncologist y el Dr. Óscar Rodríguez Faba @RodriguezFaba. La Dra. Sara Coca @scocmem abre la sesión analizando el papel de los biomarcadores en la toma de decisiones terapéuticas y plantea una cuestión clave: ¿ha llegado el momento de incorporar el ADN tumoral circulante (ctDNA) a la práctica clínica? #BladderCancer #ctDNA #Biomarcadores #MedicinaDePrecisión #UroOncología @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1 @Uro_Oncologist

Actas Urológicas Españolas recognizes Dr. Christa Gernhold as Reviewer of the Month, thanking her for her commitment and dedication to the scientific peer-review process. 👏 Thank you for your valuable contribution to the journal. #ActasUrologicas #AEU #Urology #PeerReview

Adverse effects from intravesical BCG are common, but early detection and multidisciplinary management can support treatment adherence. New practical recommendations in @actasurologicas elsevier.es/en-revista-actas… #BladderCancer #BCG #Urology

Cuando la evidencia no es intercambiable: límites de la equivalencia terapéutica en la recidiva bioquímica de alto riesgo en cáncer de próstata elsevier.es/es-revista-actas…

📢 This month in @actasurologicas : Higher baseline urinary pH was associated with lower recurrence risk after BCG in NMIBC. A simple, accessible potential biomarker deserving prospective validation. elsevier.es/en-revista-actas…

Real-world management of high-risk NMIBC remains suboptimal. Despite guideline recommendations, maintenance BCG is underused, recurrences remain frequent, and radical cystectomy is rarely performed. tandfonline.com/doi/full/10.…

KEYNOTE-905/EV-303 in @NEJM: perioperative enfortumab vedotin + pembrolizumab vs surgery alone in cisplatin-ineligible MIBC (n=344). pCR: 57.1% vs 8.6% 2-year EFS: 74.7% vs 39.4% (HR 0.40) 2-year OS: 79.7% vs 63.1% (HR 0.50) The perioperative standard in cisplatin-ineligible MIBC. doi.org/10.1056/NEJMoa251167… #BladderCancer #MIBC #GUOncology

📘 New in @actasurologicas Testicular cancer survivors remain at risk of long-term endocrine complications. This review highlights hypogonadism, infertility, bone health and thyroid dysfunction, emphasizing the need for structured survivorship care. elsevier.es/en-revista-actas…

La revista Actas Urológicas Españolas reconoce al Dr. Juan Francisco Monzón Falconi como Revisor del mes de julio, agradeciendo su compromiso y dedicación en el proceso de revisión científica. #AEU #ActasUrológicasEspañolas

This month in @actasurologicas A novel continuous high-flow retrograde irrigation technique during #PCNL showed promising preliminary results: ✅100% technical success ✅93% stone-free rate ✅0% fragment migration. elsevier.es/en-revista-actas…

The 3rd Multidisciplinary Meeting to Discuss Gaps in Genitourinary Tumours has come to an end. We would like to sincerely thank all the faculty members, moderators, panelists, participants and industry partners who contributed to making this meeting such a success.

📍 Hoy estamos en Barcelona acompañando a los Dres. @Maroto5Pablo @RodriguezFaba @Gemmas3108 en el 3rd Multidisciplinary Meeting to Discuss Gaps in Genitourinary Tumors. Durante dos jornadas, especialistas de diferentes disciplinas compartirán conocimiento, debatirán retos clínicos y analizarán nuevas estrategias para seguir avanzando en el manejo de los tumores genitourinarios. ¡Comenzamos! @GuardConsortium

📍 Desde Barcelona, en el 3rd Multidisciplinary Meeting to Discuss Gaps in Genitourinary Tumors. Dos días de debate multidisciplinar sobre los retos pendientes en #TumoresGU, de la mano de oncología médica, urología y oncología radioterápica. Con los Dres. @Maroto5Pablo @RodriguezFaba y @Gemmas3108 al frente de este encuentro.  #GUARDConsortium #GUOncology #Oncología

Secuelas endocrinas a largo plazo del cáncer testicular: manifestaciones clínicas, mecanismos y consideraciones para el seguimiento elsevier.es/es-revista-actas…

📚 New issue out now! Actas Urológicas Españolas Vol. 50, No. 6 (July/August) is now available. Discover the latest research, clinical advances and expert perspectives in Urology. 👉 elsevier.es/es-revista-actas… 📖 Available in Spanish and English. @CAU_URO @InfoAeu

📣 ¡En dos semanas! 3rd Multidisciplinary Meeting to Discuss Gaps in Genitourinary Tumors 📅 9 y 10 de julio 📍 Barcelona 🩺 Coordinan los Dres. @Maroto5Pablo, @RodriguezFaba y @Gemmas3108 👥 Participan en el encuentro @BarbaraJereczek @GeorgiaAnpa @AlbertoBreda1 @Antoniojcond @DominguezEscrig @Uro_Oncologist @drenriquegrande @mjuanfi81 @LAUrology_NL @AndreaNecchi @BertrandTOMBAL @evanguelosx @OncoBellmunt @npap69 QUEDAN POCAS PLAZAS 👉 tacticsmd.net/actividad/3rd-…

⏳ Just a few days to go! Join us in Barcelona for the 3rd Multidisciplinary Meeting to Discuss Gaps in Genitourinary Tumours. Cutting-edge discussions on #NMIBC, #MIBC, #ctDNA, GU oncology and more. Register: LINK: app.bipeek.com/registro-even… CÓDIGO DESCUENTO: ORGGUARDGU

📣 Menos de un mes!  3rd Multidisciplinary Meeting to Discuss Gaps in Genitourinary Tumors 📅 9 y 10 de julio de 2026 📍 Barcelona 🩺 Coordinan los Dres. @Maroto5Pablo, @RodriguezFaba y @Gemmas3108 👥 Entre los ponentes los Dres: @BarbaraJereczek @GeorgiaAnpa @AlbertoBreda1 @Antoniojcond @DominguezEscrig @Uro_Oncologist @drenriquegrande @mjuanfi81 @LAUrology_NL @AndreaNecchi @BertrandTOMBAL @evanguelosx @OncoBellmunt @npap69 PROGRAMA e INSCRIPCIONES 👉 tacticsmd.net/actividad/3rd-… @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1